Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Virtual Reality Platform to Facilitate Training on Treatment of Lower Limb Spasticity With OnabotulinumtoxinA
Movement Disorders
S32 - Movement Disorders: Dystonia and Tremor Disorders (3:54 PM-4:06 PM)
003

OnabotulinumtoxinA is safe and effective for treating lower limb spasticity (LLS). Treatment outcomes and adverse events may be affected by injector training and experience. Treatment of LLS with onabotulinumtoxinA requires an understanding of muscle anatomy, dosing, and injection techniques.

To assess the benefits of a virtual reality (VR)–based training platform.

A VR-based platform employing an immersive experience with haptic technology was designed to provide training on the use of onabotulinumtoxinA for LLS to increase treatment consistency and enhance knowledge and injection competency. In a pilot program conducted from December 2020 through August 2021, US-based medical trainees underwent one-on-one training on lower limb anatomy and injection guidance, then assessed the platform by completing pre- and post-training surveys. 

Six medical students, 124 residents, and 10 fellows from 21 academic centers completed pre−VR-training surveys; 111 completed post−VR-training surveys. Average learning time per VR session was ~43 minutes. The percentage of participants who were very comfortable with localization of lower limb muscles increased from 8% pre−VR-training to 14% post−VR-training. Percentages of participants identifying all correct responses almost doubled from pre−VR-training to post−VR-training when asked about possible functions of the flexor digitorum longus (12% vs 22%) and what muscles to consider injecting in a hypothetical poststroke patient (21% vs 40%). Pre−VR-training, 46% and 34% of respondents indicated that a VR-based training tool would be very or extremely useful, respectively; post−VR-training responses were 33% and 52%, respectively. Top features participants found beneficial were the realistic feel of needle insertion/removal (82%) and the ability to use injection guidance (79%).

Preliminary results suggest medical trainees have incomplete baseline knowledge and the potential need for additional training experience, for which VR may be useful. VR training duration and additional interventions to optimize training need to be defined.

Authors/Disclosures
Kimberly Ifantides
PRESENTER
No disclosure on file
Erin McGonigle, MD No disclosure on file
No disclosure on file
Alberto Esquenazi, MD (Department of Physical Medicine and Rehabilitation) Dr. Esquenazi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen and Allergan. Dr. Esquenazi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen and Allergan. The institution of Dr. Esquenazi has received research support from Ipsen, Allergan and Merz.
No disclosure on file
Monica Verduzco-Gutierrez (UT Health San Antonio) No disclosure on file
Amin Boroujerdi, PhD (Allergan R&D) No disclosure on file
Adam Buser, PhD (Allergan) Dr. Buser has received personal compensation for serving as an employee of AbbVie. Dr. Buser has received stock or an ownership interest from AbbVie.
No disclosure on file
No disclosure on file
Aleksej Zuzek, PhD (Allergan) Dr. Zuzek has received personal compensation for serving as an employee of AbbVie Inc.. Dr. Zuzek has stock in AbbVie Inc..